1	•
1	
7	
('n
~	J

Notice of Allowability

Application No.	Applicant(s)
09/955,407	ROSEN, HUGO R.
Examiner	Art Unit
Celine X Qian	1636

-			Í
	Celine X Qian	1636	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this app or other appropriate communication GHTS. This application is subject to	olication. If not include will be mailed in que	ed course. THIS
1. This communication is responsive to the amendment filed of	on 7/20/04.		
2. ☑ The allowed claim(s) is/are <u>35-40</u> .			
3. \boxtimes The drawings filed on <u>12 September 2001</u> are accepted by	the Examiner.		
4. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of noted below. Failure to timely comply will result in ABANDONMITHIS THREE-MONTH PERIOD IS NOT EXTENDABLE. 5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give 6. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftspersor 1) hereto or 2) to Paper No./Mail Date (b) including changes required by the attached Examiner's Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.8 each sheet. Replacement sheet(s) should be labeled as such in the paper No./Mail Date attached Examiner's comment regarding REQUIREMENT F	been received. been received in Application No cuments have been received in this re	complying with the requestion of the front (not the lates).	juirements OTICE OF
Attachment(s) 1. ☐ Notice of References Cited (PTO-892) 2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Statemen	PTO-413), ent/Comment of Reasons for Allov	vance
	<i></i>	Anne-Marie	Jalk

ANNE-MARIE FALK, PH.D PRIMARY EXAMINER

EXAMINER'S AMENDMENT

The after final amendment filed on 7/20/04 has been entered.

An extension of time under 37 CFR 1.136(a) is required in order to make an examiner's amendment which places this application in condition for allowance. During a telephone conversation conducted on 8/3/04, Applicant's representative Susan Alpert Siegel authorized the Director to charge Deposit Account No. 02-4550 the required fee for the extension of one month and authorized the following examiner's amendment. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claim 35: A method of identifying a preferred liver transplant donor, comprising determining in both alleles of an individual the presence or absence of a preferred genotype at a polymorphic site, wherein said preferred genotype is a guanine (G) at position -380 in a gene encoding tumor necrosis factor α (TNF- α) relative to the transcription start site, and measuring the activity of said TNF- α , [and wherein said preferred genotype is associated with decreased activity of tumor necrosis factor α (TNF- α),] wherein the presence of said preferred genotype is associated with a decrease in the activity of TNF- α and indicates that said individual is a preferred liver transplant donor.

Claim 36: A method for selecting a preferred liver for transplantation, comprising (a) determining in one or more potential liver donors the presence or absence of a preferred genotype at a polymorphic site, and measuring the activity of TNF-a, [said preferred genotype

Application/Control Number: 09/955,407 Page 3

Art Unit: 1636

associated with altered activity of tumor necrosis factor- α (TNF- α),] wherein said preferred genotype is a guanine (G) at position –380 relative to the transcription start site in both alleles in a gene encoding TNF- α ; (b) harvesting a liver, or functional portion thereof, having the preferred genotype associated with decreased TNF- α activity; thereby selecting a preferred liver for transplantation.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Celine X Qian whose telephone number is 571-272-0777. The examiner can normally be reached on 9:30-6:00 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel Ph.D. can be reached on 571-272-0781. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Celine Qian, Ph.D.

Anne-Marie Falk, PH.D